Media coverage about CRISPR THERAPTC (NASDAQ:CRSP) has trended somewhat positive recently, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CRISPR THERAPTC earned a news sentiment score of 0.04 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 47.2713580560459 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
A number of brokerages have recently weighed in on CRSP. Cann assumed coverage on CRISPR THERAPTC in a research note on Monday, July 17th. They issued a “market perform” rating on the stock. Barclays PLC reiterated a “buy” rating and issued a $29.00 price objective on shares of CRISPR THERAPTC in a research note on Friday, September 8th. Chardan Capital reiterated a “buy” rating on shares of CRISPR THERAPTC in a research note on Monday, August 14th. SunTrust Banks, Inc. initiated coverage on CRISPR THERAPTC in a research note on Thursday, July 13th. They issued a “hold” rating and a $16.00 price objective on the stock. Finally, Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of CRISPR THERAPTC in a research report on Tuesday, July 18th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $23.08.
CRISPR THERAPTC (NASDAQ CRSP) traded up 2.190% during midday trading on Friday, hitting $18.895. The company’s stock had a trading volume of 59,474 shares. CRISPR THERAPTC has a 12 month low of $14.50 and a 12 month high of $25.00. The company’s 50 day moving average price is $18.75 and its 200 day moving average price is $18.75. The firm’s market cap is $766.97 million.
CRISPR THERAPTC (NASDAQ:CRSP) last announced its quarterly earnings results on Thursday, August 10th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.06. CRISPR THERAPTC had a negative net margin of 406.61% and a negative return on equity of 47.46%. The business had revenue of $3.60 million during the quarter, compared to analysts’ expectations of $3.29 million. CRISPR THERAPTC’s quarterly revenue was up 350.0% on a year-over-year basis. Analysts expect that CRISPR THERAPTC will post ($2.43) EPS for the current year.
In related news, CEO Rodger Novak sold 75,795 shares of CRISPR THERAPTC stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $20.25, for a total value of $1,534,848.75. Following the completion of the transaction, the chief executive officer now owns 1,232,697 shares in the company, valued at $24,962,114.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kurt Von Emster sold 50,477 shares of CRISPR THERAPTC stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $17.81, for a total transaction of $898,995.37. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 449,522 shares of company stock valued at $8,713,604. Company insiders own 39.98% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “CRISPR THERAPTC (CRSP) Earns Media Sentiment Score of 0.04” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/27/crispr-theraptc-crsp-getting-somewhat-positive-news-coverage-study-finds.html.
CRISPR THERAPTC Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for CRISPR THERAPTC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR THERAPTC and related companies with MarketBeat.com's FREE daily email newsletter.